Needless to say, I'm not alone in my beliefs, because some are reporting that the decision to drop the endorsement of the anti-cancer drug Avastin was based on monetary factors (i.e., it is too expensive from the government's perspective to provide the drug).
Source: London Telegraph
The FDA advisory panel has now voted 12-1 to drop the endorsement for breast cancer treatment. The panel unusually cited "effectiveness" grounds for the decision. But it has been claimed that "cost effectiveness" was the real reason ahead of reforms in which the government will extend health insurance to the poorest...
During the debate, those opposed to the reforms cited Britain’s National Institute for Clinical Excellence, which decides whether new treatments should be made available on the NHS on the basis of cost effectiveness, as an example of the sort of drug rationing that amounted to a "death panel".